Summary

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 48 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 7, 2, 18 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Lymphoma, Pancreatic Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Peritoneal Cancer, Small-Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Non-Hodgkin Lymphoma, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Follicular Lymphoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cardiovascular Risk Factors, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dermatitis (Eczema), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Unspecified Cancer, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vitiligo and Vulvar Cancer.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope